ClinicalTrials.gg
CompletedNCT00467376Updated Sep 15, 2009

Insulin Glulisine, Insulin Lispro and Insulin Glargine in Type 1 or 2 Diabetes Mellitus

A Phase 3 interventional study of Insulin Glulisine and Lispro in Diabetes Mellitus, sponsored by Sanofi. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2009-09-15.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
485
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing insulin glulisine in Diabetes Mellitus — none open to participants now, none under way, none of them phase 3. insulin glulisine · Diabetes Mellitus.

Enrollment
3rd of 16
485 · median 169
Started
2007
with 5 others
Phase 3
6 of 17
none open now
Registered
6th of 17
by date
Lead sponsor
7 of 17
Sanofi

Among the 17 studies testing insulin glulisine in Diabetes Mellitus, this one is the 3rd largest by enrollment of the 16 interventional ones that give a count, is one of 6 that started in 2007, is one of 6 in phase 3, and was the 6th registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

None of the 17 studies testing insulin glulisine in Diabetes Mellitus is open now. The open studies under Diabetes Mellitus, anywhere →

About insulin glulisine

insulin glulisine: first FDA approval 2004 (APIDRA SOLOSTAR), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing insulin glulisine in Diabetes Mellitus as a file.
02

Study summary

Primary:

  • To compare the efficacy and safety of Insulin Glulisine to Insulin Lispro in subjects with type 1 or type 2 diabetes mellitus.
  • To compare the frequency of hypoglycemia of Insulin Glulisine to Insulin Lispro.

Secondary:

  • To compare Insulin Glulisine to Insulin Lispro in terms of the change in HbA1c at weeks 12, blood glucose parameters, insulin doses and treatment satisfaction in subjects with type 1 or type 2 diabetes mellitus
03

Conditions studied

  • Diabetes Mellitus

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 1 or type 2 diabetic patients
  • Measure 6.5% to 11.0% at visit 1
  • More than 3 months of continuous insulin treatment immediately prior to study entry

Exclusion criteria

Exclusion Criteria:

  • Pregnant women

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
485 participants (actual)

Study arms

  • Experimental
    1

    Administration of Insulin Glulisine

    Drug: Insulin Glulisine · Drug: Insulin Glargine

  • Active comparator
    2

    Administration of Lispro

    Drug: Lispro · Drug: Insulin Glargine

Interventions

06

What researchers measure

Primary outcomes

  1. Hypoglycemic episodes

    Time frame: From the beginning to end of the study

  2. Change in HbA1c

    Time frame: From baseline to endpoint

  3. Adverse events

    Time frame: From the beginning to the end of study

Secondary outcomes

  1. Change in HbA1c

    Time frame: From baseline to weeks 12

  2. blood glucose parameters, hypoglycemic episodes and dosage of the mealtime and Lantus.

    Time frame: from baseline to week 12

07

Study locations

1 site
  • Sanofi-Aventis
    Beijing, China
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2007 and a primary completion of Jun 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2007
First posted
Apr 30, 2007
Start
Jan 2007
Primary completionActual
Jun 2008
Last update
Sep 15, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00467376
Lead sponsor
Sanofi
First posted
Apr 30, 2007
Start date
Jan 2007
Primary completion
Jun 2008
Last update
Sep 15, 2009

Study contacts

Jing Fu
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin glulisine

Start the discussion